Last updated: 2026-09-05 11:20:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CareDx, Inc. (CDNA) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $50,83, with a market capitalization of $2,58B and a P/E ratio of 23,24. Over the past 52 weeks, its price has ranged from $12,37 to $53,67. This page covers its latest market performance, valuation, price trends and company information.
$2,58B | |
$49,73 | |
$99,83 | |
$0,76 | |
$49,86 | |
890,60K | |
-- | |
23,24 | |
$53,67 | |
$12,37 | |
-- | |
-- |
CareDx, Inc. (CDNA) last closed at $49,86 as of 2026-09-04 23:58:00, unchanged from the previous close of $49,86.
During the latest regular trading session, CDNA traded between $0,76 and $99,83, with a volume of 890,60K shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, CareDx, Inc. (CDNA) moved from $49,16 to $50,83, representing a gain of 3,39% ($1,67).
The stock traded between $48,81 and $51,22 during the period. The latest price is near the upper end of the 7-day range, indicating moderate upward.
The average daily volume was 1,14 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 93,1%
CDNA is currently trading at $50,83, placing it 93,1% of the way from its 52-week low of $12,37 to its 52-week high of $53,67. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 765 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CareDx, Inc. (CDNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.